Melior Pharmaceuticals I, Inc.
Records under this name other than the patents Melior Pharmaceuticals I, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Back to Melior Pharmaceuticals I, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,188,651 | Methods Of Treating Sleep Disorders Held by another company In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 11,351,169 | Methods Of Treating Dyskinesia And Related Disorders Held by another company In force · High confidence | In force | High confidence | |
| US 12,048,697 | Methods Of Treating Dyskinesia And Related Disorders Held by another company In force · High confidence | In force | High confidence | |
| US 10,786,503 | Treatment Of Adipocytes Formerly held In force · High confidence | In force | High confidence | |
| US 11,534,442 | Treatment Of Adipocytes Formerly held In force · High confidence | In force | High confidence | |
| US 12,064,432 | Treatment Of Adipocytes Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,776,870 | Methods for modulating Lyn kinase activity and treating related disorders Term ended Term ended Aug 22, 2026 · USPTO record | Term ended | Term ended Aug 22, 2026 | USPTO record |
| US 8,343,985 | Methods for modulating Lyn kinase activity and treating related disorders Term ended Ended no later than Aug 22, 2026 · USPTO record | Term ended | Ended no later than Aug 22, 2026 | USPTO record |
| US 8,835,448 | Methods and formulations for modulating lyn kinase activity and treating related disorders Term ended Ended no later than Aug 22, 2026 · USPTO record | Term ended | Ended no later than Aug 22, 2026 | USPTO record |
| US 9,216,959 | Methods and formulations for treating cardiovascular disease Term ended Term ended Aug 22, 2026 · USPTO record | Term ended | Term ended Aug 22, 2026 | USPTO record |